S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NYSE:NVST

Envista (NVST) Stock Price, News & Analysis

$19.96
+0.21 (+1.06%)
(As of 04/19/2024 ET)
Today's Range
$19.71
$20.00
50-Day Range
$19.16
$22.87
52-Week Range
$18.95
$39.28
Volume
1.17 million shs
Average Volume
2.02 million shs
Market Capitalization
$3.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.60

Envista MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
48.3% Upside
$29.60 Price Target
Short Interest
Bearish
6.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.59mentions of Envista in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.29%
From $1.43 to $1.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

274th out of 909 stocks

Dental Equipment & Supplies Industry

2nd out of 3 stocks

NVST stock logo

About Envista Stock (NYSE:NVST)

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

NVST Stock Price History

NVST Stock News Headlines

Double your money before lunch?
Unlike bacterial infections, viral infections can be difficult to treat with medicine. Usually, if you've got a virus, your doctor's best advice is to simply rest and allow your immune system to fight back. Antiviral medications prevent viruses from reproducing, but they can't actually stop the virus. However, scientists may have just found a new way to fight back.
Envista Names Paul Keel CEO
Envista Announces CEO Appointment
Envista (NYSE:NVST) Sets New 1-Year Low at $19.73
Double your money before lunch?
Unlike bacterial infections, viral infections can be difficult to treat with medicine. Usually, if you've got a virus, your doctor's best advice is to simply rest and allow your immune system to fight back. Antiviral medications prevent viruses from reproducing, but they can't actually stop the virus. However, scientists may have just found a new way to fight back.
Envista Schedules First Quarter 2024 Earnings Call
NVST Envista Holdings Corporation
Piper Sandler Keeps Their Hold Rating on Envista Holdings (NVST)
See More Headlines
Receive NVST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Envista and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Dental equipment & supplies
Sub-Industry
N/A
Employees
12,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.60
High Stock Price Target
$45.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+48.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
11 Analysts

Profitability

Net Income
$-100,200,000.00
Pretax Margin
-2.14%

Debt

Sales & Book Value

Annual Sales
$2.57 billion
Cash Flow
$2.55 per share
Book Value
$24.35 per share

Miscellaneous

Free Float
169,793,000
Market Cap
$3.43 billion
Optionable
Optionable
Beta
1.35
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

NVST Stock Analysis - Frequently Asked Questions

Should I buy or sell Envista stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Envista in the last year. There are currently 3 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVST, but not buy additional shares or sell existing shares.
View NVST analyst ratings
or view top-rated stocks.

What is Envista's stock price target for 2024?

11 Wall Street research analysts have issued 12-month target prices for Envista's stock. Their NVST share price targets range from $19.00 to $45.00. On average, they predict the company's share price to reach $29.60 in the next twelve months. This suggests a possible upside of 48.3% from the stock's current price.
View analysts price targets for NVST
or view top-rated stocks among Wall Street analysts.

How have NVST shares performed in 2024?

Envista's stock was trading at $24.06 at the beginning of 2024. Since then, NVST stock has decreased by 17.0% and is now trading at $19.96.
View the best growth stocks for 2024 here
.

Are investors shorting Envista?

Envista saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 10,840,000 shares, an increase of 23.9% from the March 15th total of 8,750,000 shares. Based on an average daily trading volume, of 2,450,000 shares, the days-to-cover ratio is currently 4.4 days.
View Envista's Short Interest
.

When is Envista's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NVST earnings forecast
.

How can I listen to Envista's earnings call?

Envista will be holding an earnings conference call on Wednesday, May 1st at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Envista's earnings last quarter?

Envista Holdings Co. (NYSE:NVST) issued its earnings results on Wednesday, February, 7th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.33 by $0.04. The business earned $645.60 million during the quarter, compared to analyst estimates of $638.37 million. Envista had a negative net margin of 3.90% and a positive trailing twelve-month return on equity of 6.31%. The company's quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.52 earnings per share.

What is Amir Aghdaei's approval rating as Envista's CEO?

9 employees have rated Envista Chief Executive Officer Amir Aghdaei on Glassdoor.com. Amir Aghdaei has an approval rating of 21% among the company's employees. This puts Amir Aghdaei in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did Envista IPO?

Envista (NVST) raised $603 million in an IPO on Wednesday, September 18th 2019. The company issued 26,800,000 shares at a price of $21.00-$24.00 per share. J.P. Morgan, Goldman Sachs and Morgan Stanley served as the underwriters for the IPO and Baird, Evercore ISI, Jefferies, BofA Merrill Lynch, Credit Suisse, Stifel and William Blair were co-managers.

Who are Envista's major shareholders?

Envista's stock is owned by a number of institutional and retail investors. Top institutional investors include Leeward Investments LLC MA (0.37%), State of Michigan Retirement System (0.02%) and NBC Securities Inc. (0.01%). Insiders that own company stock include Amir Aghdaei, Curt W Bludworth, Curt W Bludworth, Eric Conley, Howard H Yu, Jeffrey Kappler, Mark E Nance, Mark E Nance, Mischa Reis and Stephen Keller.
View institutional ownership trends
.

How do I buy shares of Envista?

Shares of NVST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVST) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners